Microsatellite Instability Detection with Cell-free DNA Next-generation Sequencing

Microsatellite Instability Detection with Cell-free DNA Next-generation Sequencing

PUBLICATIONS

November 6, 2019

Society for Immunotherapy of Cancer 2019, Tempus-authored – Microsatellite instability is a clinically actionable genomic indication for cancer immunotherapy. In microsatellite instability-high (MSI-H) tumors, defects in DNA mismatch repair (MMR) can cause a hypermutated phenotype where alterations accumulate in the repetitive microsatellite regions of DNA. MSI detection is typically performed by subjecting tumor tissue (“solid biopsy”) to clinical next-generation sequencing or specific assays, such as MMR IHC or MSI PCR. Circulating cell-free tumor DNA (cfDNA) testing (“liquid biopsy”) is rapidly emerging as a less invasive method for cancer detection and monitoring disease progression. Here, we explore the possibility of detecting MSI in cfDNA and develop a novel cfDNA MSI detection assay with high specificity.

View the full publication here.

Authors: Ariane Lozac’hmeur, Jason Perera, Denise Lau, and Aly Khan